Andreas Argyrides
Stock Analyst at Oppenheimer
Total Price Targets
7
Stocks Covered
7
Sectors
Healthcare
Most Recent
Nov 24, 2025
Notable Calls (Last 12 Months)
Stocks Covered by Andreas Argyrides
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $62.00 | $35.05 | +76.9% | 1 | Nov 24, 2025 |
| BNTC | Benitec Biopharma Inc. | $29.00 | $11.91 | +143.5% | 1 | Sep 16, 2025 |
| DYN | Dyne Therapeutics, Inc. | $34.00 | $25.17 | +35.1% | 1 | Jun 2, 2025 |
| LQDA | Liquidia Corporation | $13.00 | $86.13 | -84.9% | 1 | May 19, 2025 |
| MNKD | MannKind Corporation | $10.00 | $3.90 | +156.1% | 1 | Oct 10, 2023 |
| RANI | Rani Therapeutics Holdings, Inc. | $28.00 | $0.78 | +3503.6% | 1 | Jun 13, 2022 |
| SGMO | Sangamo Therapeutics, Inc. | $5.00 | $0.07 | +6656.8% | 1 | Jun 13, 2022 |
Recent Activity
- Nov 24, 2025— Set$62.00price target onHRMY(Harmony Biosciences Holdings, Inc.)
- Sep 16, 2025— Set$29.00price target onBNTC(Benitec Biopharma Inc.)
- Jun 2, 2025— Set$34.00price target onDYN(Dyne Therapeutics, Inc.)
- May 19, 2025— Set$13.00price target onLQDA(Liquidia Corporation)
- Oct 10, 2023— Set$10.00price target onMNKD(MannKind Corporation)
- Jun 13, 2022— Set$28.00price target onRANI(Rani Therapeutics Holdings, Inc.)
- Jun 13, 2022— Set$5.00price target onSGMO(Sangamo Therapeutics, Inc.)
Frequently Asked Questions
Who is Andreas Argyrides?
Andreas Argyrides is a stock analyst at Oppenheimer covering 7 stocks primarily in Healthcare. They have issued 7 price targets since Jun 13, 2022.
What stocks does Andreas Argyrides cover?
Andreas Argyrides currently covers 7 stocks, including HRMY, BNTC, DYN, LQDA, MNKD.
What is Andreas Argyrides's latest price target?
Andreas Argyrides's most recent price target was $62.00 on HRMY (Harmony Biosciences Holdings, Inc.), set on Nov 24, 2025.
What is Andreas Argyrides's highest price target?
Andreas Argyrides's highest issued price target is $62.00 on HRMY, set on Nov 24, 2025.
More Analysts at Oppenheimer
Coverage based on publicly published price targets. Not investment advice.